MDS-445 Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes (HR MDS): 5F9005 phase 1b study results

Eitemau Tebyg

• S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS
  gan: D. A. Sallman, et al.
  Cyhoeddwyd: (2022-06-01)
• Magrolimab in combination with azacitidine for patients with untreated higher-risk myelodysplastic syndromes: 5F9005 phase 1b study results
  gan: Sallman, DA, et al.
  Cyhoeddwyd: (2022)
• MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
  gan: Garcia-Manero, G, et al.
  Cyhoeddwyd: (2021)
• Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
  gan: Garcia-Manero, G, et al.
  Cyhoeddwyd: (2021)
• Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
  gan: Garcia-Manero, G, et al.
  Cyhoeddwyd: (2021)